- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01342341
Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake
Study Overview
Detailed Description
The investigators propose a 45-day, double-blind, placebo-controlled crossover study in light to moderate and heavy alcohol users.
The specific aims are to:
- Determine if chlorzoxazone alters daily alcohol consumption by comparing the mean drinks consumed per day during chlorzoxazone administration compared with the mean drinks per day consumed during placebo administration.
- To determine if polymorphisms in genes encoding for neurotransmitters or receptors involved in alcohol reward, abuse, dependence, craving, or relapse may predict the level of response to chlorzoxazone's effects on alcohol consumption or craving.
- To investigate any change in alcohol craving during a cue induced craving task where participants view and respond to a number of images.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Emeryville, California, United States, 94608
- Ernest Gallo Clinic and Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Criteria: Healthy adults who are social drinkers 21 - 50 years of age.
- Moderate to heavy social drinkers (women=10-25 drinks/week, men=14-30 drinks/week).
- If female, must be non-lactating, not pregnant, and using a reliable contraception method (i.e. abstinence, intrauterine device [IUD], or hormonal birth control).
- Able and willing to provide written informed consent.
- Able to understand and follow the instructions of the investigator, and understand all rating scales.
Exclusion Criteria:
- Use of cocaine, amphetamines, hallucinogens, "ecstasy", opiates, sedatives, pain pills, sleeping pills, or other psychoactive drugs more than twice a week.
- A history of complicated alcohol or other drug withdrawal syndrome(s), e.g. delirium tremens or seizures.
- Current physiological dependence on any psychoactive drug (except nicotine or caffeine) including alcohol, as determined by MD or NP assessment.
- Current enrollment in an alcohol or other drug treatment program, or current legal problems relating to alcohol or other drug use, including awaiting trial or supervision by a parole or probation officer.
- Currently trying to quit using alcohol and/or "recreational" drugs.
- Clinically significant medical or psychiatric illness as determined by screening blood tests, medical history, and physical exam performed or reviewed by the study MD or NP.
- Bilirubin more than 2 times the normal upper limit.
- AST (SGOT), ALT (SGPT), or alkaline phosphatase more than 2 ½ times the normal upper limit.
- Symptoms of liver disease, as assessed by MD or NP assessment (jaundice, Hx of hepatitis, itchy skin, etc.).
- A current pregnancy, or a woman of child-bearing potential not currently using an adequate means of contraception.
- BAC level greater than 0.05% at the beginning of Screening Visit, Visit 1 or Visit 4.
- Neurological dysfunction or psychiatric disorder severe enough to interfere with assessment of outcome measures as defined above.
- Known allergy to chlorzoxazone.
- Has received an investigational drug within 30 days prior to Study Visit 2 (after screening visit).
- Subjects who are unable to read or speak English.
- Those who, in the opinion of the investigator, are considered unable to adhere to scheduled appointments, are unlikely to comply with the study protocol, or who are unsuitable for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Parafon Forte first, then Placebo
Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
|
Drug: Parafon Forte administered at study visit Other: Placebo administered at study visit
Other Names:
|
Placebo Comparator: Placebo first, then Parafon Forte
Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
|
Drug: Parafon Forte administered at study visit Other: Placebo administered at study visit
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alcohol Consumption in Drinks/Week.
Time Frame: 45 days
|
Each subject will record how many drinks/week they are consuming while on the study drug and placebo during the 45-day study.
The primary outcome of this study is to determine the effect of chlorzoxazone on alcohol consumption.
Reduction in alcohol consumption is measured utilizing behavioral inventories, electronic diaries, urine, and ethyl glucuronide.
|
45 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Howard Fields, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chlorzoxazone
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Abuse
-
The Morton Center, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA)UnknownAlcohol Dependence | Cannabis Dependence | Alcohol Abuse | Cannabis Abuse | Other Substance AbuseUnited States
-
Michael E. DeBakey VA Medical CenterUnknownAlcohol Dependence | Alcohol Abuse | Substance Abuse ProblemUnited States
-
Polaris Health DirectionsUniversity of Massachusetts, WorcesterCompletedAlcohol Abuse, Alcohol DependenceUnited States
-
Kent State UniversityCompletedAlcohol Use Disorder | Alcohol Abuse | Alcohol Abuse, EpisodicUnited States
-
Australian National UniversityUniversity of Peradeniya; Department of Foregin Affairs and Trade, AustraliaCompletedIntimate Partner Violence | Domestic Abuse | Drug and Alcohol AbuseAustralia
-
National Institute on Drug Abuse (NIDA)CompletedDrug/Substance Abuse/Addiction | Alcohol Abuse/AddictionUnited States
-
Queen Mary University of LondonBarts & The London NHS Trust; University of HertfordshireRecruitingAlcohol Use Disorder | Alcohol Abuse or DependenceUnited Kingdom
-
National Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Drug Abuse | Alcohol AbuseUnited States
-
Baylor College of MedicineCompletedAlcohol Dependence | Substance Abuse | Alcohol AbuseUnited States
-
Fundació Sant Joan de DéuInstituto de Salud Carlos III; European Union; University of Barcelona; Red Salud...UnknownAlcohol Abuse in PregnancySpain
Clinical Trials on Parafon Forte
-
Allergopharma GmbH & Co. KGCompletedAllergy | Rhinitis | ConjunctivitisGermany
-
Ain Shams UniversityCompletedHyperactivity | Impulsivity | InattentiveEgypt
-
Hams Hamed AbdelrahmanCompleted
-
University of Medicine and Dentistry of New JerseyAVVAA World Healthcare Products, Inc.TerminatedPsoriasis | Eczema
-
Sherief Abd-ElsalamRecruiting
-
University of IbadanCompletedParkinson DiseaseNigeria
-
Al-Azhar UniversityCompleted
-
Cairo UniversityUnknown
-
Bitop AGCompleted
-
Galderma R&DCompletedAcne Vulgaris | Atrophic Acne ScarsFrance, Canada